Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia

ConclusionThe pharmacokinetics of PEGasparaginase in infants diagnosed under one year of age with ALL is comparable to that of older children (1 –18 years). We recommend a PEGasparaginase dosing at 1,500 IU/m2 for infants without dose adaptations according to age, and implementing therapeutic drug monitoring as standard practice.
Source: Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research